In Q2 2026, Vir Biotechnology, Inc. reported significant revenue growth, reaching $238.95 million compared to just $1.21 million a year prior. This translated into a net income of $80.08 million, a turnaround from a $110.96 million loss, marking a positive shift in earnings per share. However, despite this improvement, the company missed analyst expectations for both earnings and sales. Key developments include a $240 million collaboration with Astellas to support its oncology initiatives, which, while enhancing cash resources, underscores the risks tied to its reliance on early-stage oncology programs. Moving forward, the company projects revenue of $171.2 million and earnings of $32.5 million by 2029, with a fair value estimate of $21.56 per share suggesting a significant potential upside.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/what-vir-biotechnology-virs-profit-swing-but-earnings-miss-m
